EU Patent Dispute Outcome Limits DMD Opportunity for AVI Biopharma

EU Patent Dispute Outcome Limits DMD Opportunity for AVI Biopharma
Prosensa announced the outcome of the Opposition Division of the European Patent Office (EPO) ruling on dystrophin exon 51 skipping molecule. Wedbush Securities said the EPO decision, pending any appeal, may effectively prevent AVI BioPharma from marketing its lead exon 51 skipping molecule, eteplirsen, for Duchenne Muscular Dystrophy in the European Union without a license.